COPD trials in Chile

In Chile 6 Also abroad 559

6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Where
Chile, Concepción, Santiago, Talca, Temuco, Viña del Mar
Age
40 years and over
People
987 worldwide
Run by
AstraZeneca
See details and how to joinNCT07082738
Phase 3Taking people
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Where
Chillan, Recoleta, Santiago, Temuco, Viña del Mar
Age
40 years to 80 years
People
942 worldwide
Run by
Sanofi
See details and how to joinNCT07190222 · EU 2024-518213-25-00
Phase 3Taking people
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Where
Santiago, Talca, Valdivia, Viña del Mar
Age
40 years to 80 years
People
942 worldwide
Run by
Sanofi
See details and how to joinNCT07190209 · EU 2024-518016-39-00
Phase 3Taking people
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Where
Curicó
Age
40 years to 80 years
People
981 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06959095 · EU 2024-520418-22-00
Phase 3Taking people
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Where
Curicó, Quillota, Santiago, Talca, Temuco, Victoria, Viña del Mar, Vitacura
Age
40 years to 80 years
People
5,250 worldwide
Run by
AstraZeneca
See details and how to joinNCT06283966 · EU 2023-507407-59-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Where
Chile, Concepción, Curicó, Quillota, Santiago, Talca
Age
40 years to 80 years
People
990 worldwide
Run by
AstraZeneca
See details and how to joinNCT06883305 · EU 2024-517458-90-00